I would just note that this hypothesis seems to be wrong given my conversation with Adam Salmon a while back. At least he believes that the longevity effects of rapamycin are likely the AUC, not the peak (CMax) levels of rapamycin.
I asked him, in this interview: Adam Salmon's Marmoset Longevity Study
Currently, I think many scientists (Dudley Lamming, etc.) think its the trough levels of rapamycin are the most important factor in side effects. The higher the trough level, the greater the side effects (due to mTORC2 inhibition) is the hypothesis.
2 Likes